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Abstract 
 
Optically active polyheterocycles containing pyrrolidine, imidazole and 1,2,3-triazole 
units were obtained via a multistep synthesis with the [3+2] cycloaddition of Boc-
protected (S)-(pyrrolidin-2-yl)methyl azide with 2-ethynylimidazoles in the presence of 
CuI (CuAAC reaction) as the key step. Typical for terminal alkynes, the reactions 
occurred regioselectively and 1,4-disubstituted 1,2,3-triazoles were formed exclusively. 
The deprotection of the pyrrolidine N-atom was performed by treatment with TFA 
under standard conditions. 
 
1. Introduction 
 
Optically active bisheterocycles containing the chiral pyrrolidine skeleton and an 
imidazole ring can conveniently be prepared from N-protected (S)-prolinamine, 
formaldehyde, and the corresponding α-hydroxyimino ketones.2 The initially obtained 
imidazole N-oxides of type 1 can by transformed into other imidazole derivatives via 
deoxygenation, rearrangement, sulfur transfer, and O-alkylation. Recently, the 
unexpected formation of the polyheterocycles 2 via heterocyclization of bisheterocycles 
1, containing the N-deprotected pyrrolidine upon treatment with Ac2O was reported 
(Scheme 1).3 
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Scheme 1. 
 
On the other hand, the 2-unsubstituted imidazoles are known to undergo ethynylation by 
treatment of the corresponding 2-iodo derivative with a silylated acetylene in the 
presence of Pd(PPh3)4, CuI, and an organic base (Sonogashira-type alkynylation).4 The 
obtained 2-ethynylimidazoles were used for the reaction with different azides yielding 
the 1,2,3-triazole-functionalized imidazoles as biologically active compounds. 
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In search for optically active polyheterocycles derived from (S)-proline, a series of 2-
unsubstituted imidazole N-oxides of type 1 was used as substrates for the conversion 
into optically active polyheterocycles containing a 1,2,3-triazole residue along with 
imidazole and proline units. 
 
2. Results and discussion 
 
The 2-unsubstituted imidazole N-oxides 3 were prepared according to the known 
procedure,5 and subsequently deoxygenated using Raney-Ni in methanolic solution at 
room temperature.6 The imidazoles 4 obtained thereby were treated with LDA in THF at 
-78 °C and iodinated yielding the desired 2-iodo derivatives 5 (see ref. 4) in good to 
excellent yields (Scheme 2). 
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Scheme 2. 
 
The next step comprises the reaction of 5 with (trimethylsilyl)acetylene in the presence 
of catalytic amounts of Pd(PPh3)4 and CuI in triethylamine as the solvent at 50 °C. The 
obtained products were desilylated using tetrabutylammonium fluoride (TBAF). After 
chromatographic purification, the 2-ethynylimidazoles 6 were isolated and characterized 
by spectroscopic methods. The most characteristic change in the 1H NMR spectra in 
comparison with imidazoles 4 was the signal for the acetylenic CH between 3.23 and 
3.58 ppm. 
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In the final step, the azide 7 derived from the Boc-protected (S)-proline was reacted 
with imidazoles 6 following a ‘click’ procedure. However, these reactions, performed in 
acetonitrile solution at 40 °C, required 2 h for complete conversion. The deprotection of 
the pyrrolidine ring was carried out in a typical manner using TFA in dichloromethane 
solution. In analogy to Cu(I)-catalyzed cycloadditions of organic azides to non-
symmetric acetylenic dipolarophiles, the reactions leading to 8 occurred with complete 
regioselectivity. Based on the generally known course of these Cu-catalyzed [3+2] 
cycloadditions with terminal acetylenes,7 the structure of the sterically less crowded 
isomers of type 8 was attributed to all products obtained. The regioselectivity of the 
studied azide-alkyne [3+2]-cycloaddition reactions was unambiguously confirmed by 
2D spectroscopic methods. For example, in the case of 8c, the HMBC spectrum showed 
the correlation of atoms C(5)H of the 1,2,3-triazole ring and CH2 of the N(1)CH2 
bridge. Moreover, correlation of two protons of the N(1)CH2 group with the C(5) atom 
of the 1,2,3-triazole unit was also found. 
The optically active azide 7 is an attractive building block for the synthesis of optically 
active 1,2,3-triazoles via the [3+2] cycloaddition with differently substituted acetylenes. 
Diverse protocols are known for this reaction. Although the classical, non-catalyzed 
reaction was also reported recently,8 in general, the cycloaddition was efficiently 
catalyzed by metal catalysts, such as Cu(I) salts8a,9,10 and Ru(I) or Ir(I) complexes.11 
Depending on the reaction conditions, the formation of 1,2,3-triazole derivatives occurs 
with complete regioselectivity or a mixture of the regiosiomers is formed.8a,11 Typically, 
bisheterocycles containing a pyrrolidine and a 1,2,3-triazole ring are reported as 
products obtained with terminal acetylenes. Trisheterocyclic systems were prepared 
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from 7 and 2-ethynylpyridine12 and 1-methyl-3-propargylimidazolium chloride,13, 
respectively. Using analogous methods, tetra- and pentaheterocyclic compounds with 
one or two 1,2,3-triazole rings were also synthesized.12,14 
 
3. Conclusions 
 
The presented results show that the azide 7 derived from (S)-proline can be efficiently 
used for the preparation of optically active 1,2,3-triazole derivatives of type 8 
containing three different N-heterocycles. To the best of our knowledge, 
polyheterocycles of this type are hitherto unknown. They contain three different 
important heterocyclic units and, therefore, can be considered as attractive model 
compounds for diverse applications. For example, imidazolyl triazoles were shown to 
act as inhibitors of biological processes.4 In addition, they may find applications as 
proline-derived ligands for asymmetric synthesis and organocatalysts. 
 
4. Experimental 
 
4.1. General 
 
Melting points were determined in a capillary using a Melt-Temp. II apparatus 
(Aldrich) or STUART SMP30 and are uncorrected. The IR Spectra were recorded on a 
NEXUS FT-IR spectrophotometer in KBr; absorptions in cm-1. The 1H and 13C{1H} 
NMR spectra were measured on a Bruker Avance III instrument (600 and 150 MHz, 
resp.) using a solvent signal as the reference. The multiplicity of signals in the 13C NMR 
spectra was established using the HMQC technique. Chemical shifts (δ) are given in 
ppm and coupling constants J in Hz. Assignments of signals in 13C NMR spectra were 
made on the basis of HMQC experiments. HR-MS: Bruker maxis spectrometer; ESI-
MS: Varian 500. Optical rotations were determined on a PERKIN–ELMER 241 MC 
polarimeter for λ = 589 nm. 
 
4.2. General procedure for the synthesis of compounds 3 
 
To a solution of imine 1 (0.129 g, 3.0 mmol) in EtOH (4 mL), a solution of an 
equimolar amount of the corresponding α-hydroxyimino ketone 2 was added and the 
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reaction mixture was heated at reflux for 3 h. Next, the solvent was removed under 
reduced pressure and the resulting residue was purified by column chromatography or 
by crystallization. 
 
The synthesis of compounds 3a5, 3c5, and 3d6 was already described in the literature. 
 
4.2.1. 1,4-Dimethyl-5-phenyl-1H-imidazole 3-oxide (3b). Yield: 0.374 g (66%). 
Colorless crystals. Mp. 128–130 °C (Et2O). IR (KBr): ν 3409br, 3147m, 1636m, 
1596m, 1501m, 1443m, 1389m, 1338m, 1164m, 1012m, 857m, 769m, 705m, 645m. 1H 
NMR (CDCl3): δ 8.06 (s, 1H, HC(2)); 7.52–7.44 (m, 3H, HC(arom.)); 7.34–7.26 (m, 
2H, HC(arom.)); 3.55 (s, 3H, Me); 2.22 (s, 3H, Me). 13C NMR (CDCl3): δ 130.0 (2 
CH(arom.)); 129.2 (1 CH(arom.)); 129.0 (2 CH(arom.)); 127.9 (C(5)); 127.3 (C(arom.)); 
126.7 (C(4)); 125.9 (C(2)); 33.1 (Me); 7.8 (Me). HR-ESI-MS (MeOH): 189.10224 
(calcd 189.10288 for C11H13N2O, [M+1]+). 
 
4.2.2. 1-Butyl-4-methyl-5-phenyl-1H-imidazole 3-oxide (3e). Yield: 0.247 g (71%). 
Colorless crystals. Mp. 82–84 °C (Et2O). IR (KBr): ν 3385br, 3079m, 2963m, 1630m, 
1595m, 1464m, 1383m, 1339m, 1165m, 1014m, 768m, 706m, 641m. 1H NMR (CDCl3): 
δ 7.97 (s, 1H, HC(2)); 7.52–7.45 (m, 3H, HC(arom.); 7.31–7.26 (m, 2H, HC(arom.); 
3.83–3.77 (m, 2H, H2C); 2.20 (s, 3H, Me); 1.60–1.52 (m, 2H, H2C); 1.25–1.16 (m, 2H, 
H2C); 0.83–0.77 (m, 3H, Me). 13C NMR (CDCl3): δ 130.1 (2 CH(arom.)); 129.3 (1 
CH(arom.)); 129.0 (2 CH(arom.)); 127.9 (C(5)); 127.6 (C(arom.)); 126.4 (C(4)); 124.8 
(C(2)); 45.8 (CH2); 32.5 (CH2); 19.3 (CH2); 13.2 (Me); 7.7 (Me). HR-ESI-MS (MeOH): 
231.14919 (calcd 231.14984 for C14H19N2O, [M+1]+). 
 
4.3. General procedure for the synthesis of compounds 4 
 
To a solution of the corresponding imidazole N-oxide 3 (1 mmol) in MeOH (3 mL), 
a suspension of freshly prepared Raney nickel in MeOH was added. After all of the 
substrate was consumed (monitored by TLC), the reaction mixture was filtered via 
celite and the solvent of the filtrate was evaporated. The obtained imidazoles 4 were 
purified by column chromatography. 
 
The synthesis of compound 4d6 was already described in the literature. 
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4.3.1. 1,4,5-Trimethyl-1H-imidazole (4a).15 Yield: 0.075 g (68%). Colorless oil 
(SiO2, AcOEt/MeOH, 8:2). IR (ﬁlm): ν 3393br, 2921m, 1648m, 1597m, 1509m, 
1450m, 1423m, 1390m, 1297m, 1233m, 1185m, 1086m, 970m, 752m. 1H NMR 
(CDCl3): δ 7.01 (s, 1H, HC(2)); 3.23 (s, 3H, MeN); 1.91 (s, 3H, Me); 1.86 (s, 3H, Me). 
13C NMR (CDCl3): δ 135.0 (C(2)); 133.2 (C(5)); 122.4 (C(4)); 31.1 (MeN); 12.5 (Me); 
7.9 (Me). HR-ESI-MS (MeOH): 111.09167 (calcd 111.09361 for C6H11N2, [M+1]+). 
 
4.3.2. 1,4-Dimethyl-5-phenyl-1H-imidazole (4b).16 Yield: 0.107 g (62%). Colorless 
oil (SiO2, AcOEt/MeOH, 8:2). IR (ﬁlm): ν 3382br, 2951m, 1605m, 1579m, 1500m, 
1441m, 1302m, 1260m, 1208m, 1080m, 1015m, 968m, 785m. 1H NMR (CDCl3): δ 
7.46–7.40 (m, 2H, HC(arom.)); 7.45 (s, 1H, HC(2)); 7.38–7.34 (m, 1H, HC(arom.)); 
7.31–7.27 (m, 2H, HC(arom.)); 3.51 (s, 3H, Me); 2.22 (s, 3H, Me). 13C NMR (CDCl3): 
δ 136.8 (C(2)); 135.7 (C(arom.)); 130.3 (C(5)); 129.8 (2 CH(arom.)); 128.7 (C(4)); 
128.6 (2 CH(arom.)); 127.7 (1 CH(arom.)); 32.4 (Me); 13.4 (Me). HR-ESI-MS 
(MeOH): 173.10732 (calcd 173.10935 for C11H13N2, [M+1]+). 
 
4.3.3. 1-Methyl-4,5-diphenyl-1H-imidazole (4c).15,17 Yield: 0.193 g (82%). Colorless 
crystals. Mp. 158–160 °C (CH2Cl2/hexane). IR (KBr): ν 3432br, 3042m, 1638m, 
1601m, 1507m, 1484m, 1444m, 1423m, 1367m, 1316m, 1250m, 1195m, 1068m, 
1021m, 953m, 917m, 772m. 1H NMR (CDCl3): δ 7.55 (s, 1H, HC(2)); 7.51–7.47 (m, 
2H, HC(arom.)); 7.45–7.40 (m, 3H, HC(arom.)); 7.34–7.31 (m, 2H, HC(arom.)); 7.21–
7.17 (m, 2H, HC(arom.)); 7.14–7.10 (m, 1H, HC(arom.)); 3.45 (s, 3H, Me). 13C NMR 
(CDCl3): δ 138.3 (C(arom.)); 137.5 (C(2)); 134.7 (C(arom.)); 130.7 (2 CH(arom.)); 
130.7 (C(5)); 129.0 (2 CH(arom.)); 128.9 (C(4)); 128.6, 128.1, 126.6, 126.3 (6 
CH(arom.)); 32.5 (Me). HR-ESI-MS (MeOH): 235.12297 (calcd 235.12457 for 
C16H15N2, [M+1]+). 
 
4.3.4. 1-Butyl-4-methyl-5-phenyl-1H-imidazole (4e). Yield: 0.177 g (83%). 
Colorless oil (SiO2, AcOEt/MeOH, 8:2). IR (film): ν 3381br, 2958m, 1606m, 1493m, 
1442m, 1380m, 1262m, 1205m, 1114m, 1015m, 968m, 918m, 702m. 1H NMR (CDCl3): 
δ 7.36 (s, 1H, HC(2)); 7.34–7.29 (m, 2H, HC(arom.)); 7.26–7.22 (m, 1H, HC(arom.)); 
7.19–7.15 (m, 2H, HC(arom.)); 3.74–3.69 (m, 2H, H2C); 2.09 (s, 3H, Me); 1.44–1.37 
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(m, 2H, H2C); 1.10–1.04 (m, 2H, H2C); 0.71–0.66 (m, 3H, Me). 13C NMR (CDCl3): δ 
135.9 (C(2)); 135.3 (C(arom.)); 130.5 (C(5)); 129.9, 128.5 (4 CH(arom.)); 128.1 (C(4)); 
127.7 (CH(arom.)); 45.0 (CH2); 32.7 (CH2); 19.5 (CH2); 13.3 (Me); 13.1 (Me). HR-ESI-
MS (MeOH): 215.15427 (calcd 215.15679 for C14H19N2, [M+1]+). 
 
4.4. General procedure for the synthesis of compounds 5 
 
To a solution of the corresponding imidazole 4 (1 mmol) in dry THF (4 mL), a 
solution of 1.5 equiv. of LDA in THF was added at –78 ºC. After 1 h, a solution of I2 in 
dry THF was added dropwise and the mixture was stirred over night at room 
temperature. Next, NH4Cl(aq) was added and the mixture extracted with AcOEt. The 
organic layers were combined and dried over Na2SO4. After filtration, the solvent of the 
filtrate was evaporated under reduced pressure. The crude products were filtered 
through a short SiO2 column. 
 
4.4.1. 2-Iodo-1,4,5-trimethyl-1H-imidazole (5a). Yield: 0.158 g (67%). Pale yellow 
crystals. Mp. 180–182 °C (MeOH/hexane). IR (KBr): ν 3432br, 2918m, 1610m, 1458m, 
1438m, 1395m, 1384m, 1274m, 1195m, 1116m, 1086m, 975m, 762m, 718m. 1H NMR 
(CDCl3): δ 3.46 (s, 3H, Me); 2.19 (s, 3H, Me); 2.15 (s, 3H, Me). 13C NMR (CDCl3): δ 
137.1, 127.0 (C(5), C(4)); 87.4 (C–I); 34.2 (Me); 12.8 (Me); 9.7 (Me). HR-ESI-MS 
(MeOH): 236.98832 (calcd 236.99005 for C6H10N2I, [M+1]+). 
 
4.4.2. 2-Iodo-1,4-dimethyl-5-phenyl-1H-imidazole (5b). Yield: 0.293 g (98%). Pale 
yellow crystals. Mp. 110–112 °C (MeOH/hexane). IR (KBr): ν 3422br, 2922m, 1636m, 
1493m, 1451m, 1386m, 1282m, 1244m, 1095m, 1014m, 920m, 795m, 753m, 700m. 1H 
NMR (CDCl3): δ 7.49–7.45 (m, 2H, HC(arom.)); 7.43–7.39 (m, 1H, HC(arom.)); 7.31–
7.26 (m, 2H, HC(arom.)); 3.50 (s, 3H, Me); 2.23 (s, 3H, Me). 13C NMR (CDCl3): δ 
137.1 (C(arom.)); 133.0 (C(5)); 130.2, 128.8, 128.7 (5 CH(arom.)); 125.6 (C(4)); 92.4 
(C–I); 35.7 (Me); 12.8 (Me). HR-ESI-MS (MeOH): 299.00397 (calcd 299.00539 for 
C11H12N2I, [M+1]+). 
 
4.4.3. 2-Iodo-1-methyl-4,5-diphenyl-1H-imidazole (5c). Yield: 0.231 g (64%). Pale 
yellow crystals. Mp. 160–162 °C (MeOH/hexane). IR (KBr): ν 3433br, 3066m, 1600m, 
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1504m, 1452m, 1401m, 1360m, 1296m, 1092m, 1071m, 975m, 915m, 770m, 693m, 
602m. 1H NMR (CDCl3): δ 7.46–7.40 (m, 5H, HC(arom.)); 7.30–7.27 (m, 2H, 
HC(arom.)); 7.18–7.14 (m, 2H, HC(arom.)); 7.13–7.09 (m, 1H, HC(arom.)); 3.39 (s, 
3H, Me). 13C NMR (CDCl3): δ 141.6, 133.9 (2 C(arom.)); 132.7, 130.8 (C(5), C(4)); 
130.8, 129.1, 129.1, 128.1, 126.7, 126.6 (10 CH(arom.)); 91.6 (C–I); 35.2 (Me). HR-
ESI-MS (MeOH): 361.01962 (calcd 361.02049 for C16H14N2I, [M+1]+). 
 
4.4.4. 1-Butyl-2-iodo-4,5-dimethyl-1H-imidazole (5d). Yield: 0.153 g (55%). Pale 
yellow crystals. Mp. 38–40 °C (MeOH/hexane). IR (KBr): ν 3373br, 2958m, 1597m, 
1467m, 1417m, 1370m, 1308m, 1210m, 1120m, 1010m, 980m, 765m. 1H NMR 
(CDCl3): δ 3.80–3.76 (m, 2H, H2C); 2.20 (s, 3H, Me); 2.15 (s, 3H, Me); 1.66–1.59 (m, 
2H, H2C); 1.42–1.34 (m, 2H, H2C); 0.99–0.95 (m, 3H, Me). 13C NMR (CDCl3): δ 136.9, 
126.4 (C(5), C(4)); 87.3 (C–I); 47.4 (CH2); 32.4 (CH2); 19.9 (CH2); 13.7 (Me); 12.7 
(Me); 9.5 (Me). HR-ESI-MS (MeOH): 279.03527 (calcd 279.03650 for C9H16N2I, 
[M+1]+). 
 
4.4.5. 1-Butyl-2-iodo-4-methyl-5-phenyl-1H-imidazole (5e). Yield: 0.333 g (98%). 
Pale yellow crystals. Mp. 56–58 °C (MeOH/hexane). IR (KBr): ν 3057br, 2958m, 
1606m, 1582m, 1493m, 1459m, 1410m, 1274m, 1016m, 911m, 785m, 756m, 701m. 1H 
NMR (CDCl3): δ 7.50–7.42 (m, 3H, HC(arom.)), 7.32–7.29 (m, 2H, HC(arom.)), 3.79–
3.74 (m, 2H, H2C); 2.19 (s, 3H, H3C); 2.14 (s, 3H, H3C); 1.65–1.58 (m, 2H, H2C); 1.42–
1.34 (m, 2H, H2C); 0.99–0.94 (m, 3H, H3C). 13C NMR (CDCl3): δ 137.2, 132.8 (C(5), 
C(4)); 130.3 (2 HC(arom.)); 129.2 (C(arom.)); 129.9, 128.9 (3 HC(arom.)); 90.4 (C–I); 
47.8 (CH2); 32.4 (CH2); 19.6 (CH2); 13.4 (Me); 12.6 (Me). HR-ESI-MS (MeOH): 
341.05092 (calcd 341.05239 for C14H18N2I, [M+1]+). 
 
4.5. General procedure for the synthesis of compounds 6 
 
To a solution of the corresponding iodoimidazole 5 (1 mmol), Pd(PPh3)4 (0.2 
mmol), and CuI (0.4 mmol) in dry Et3N (5 mL), trimethylsilylacetylene (1.2 mmol) was 
added dropwise. The mixture was heated at 50 ºC until the substrate was consumed (ca. 
30 min). Next, the precipitate was filtered and washed with Et2O. The solvent was 
evaporated and the crude product was purified by column chromatography (Al2O3, 
AcOEt/hexane 1:9). The obtained product was dissolved in dry THF and TBAF (1.5 
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equiv.) was added to the solution at –78 ºC. After 20 min, H2O was added to the 
mixture, which was then extracted with CH2Cl2 (3 × 15 mL). The organic layers were 
combined and dried over Na2SO4. After filtration, the solvent was evaporated. The 
product 6 was purified by column chromatography (AcOEt/hexane 3:7). 
 
4.5.1. 2-Ethynyl-1,4,5-trimethyl-1H-imidazole (6a). Yield: 0.069 g (52%). Pale 
yellow oil (Al2O3, AcOEt/hexane 3:7). IR (KBr): ν 3111br, 2984m, 2098m, 1585m, 
1466m, 1405m, 1378m, 1162m, 821m, 746m, 729m. 1H NMR (CDCl3): δ 3.48 (s, 3H, 
Me); 3.23 (s, 1H, HC); 2.07 (s, 3H, Me); 2.05 (s, 3H, Me). 13C NMR (CDCl3): δ 134.5, 
128.6, 124.6 (3 C(imid.)); 80.6, 73.9 (C≡C); 31.1 (Me); 12.7 (Me); 8.9 (Me). HR-ESI-
MS (MeOH): 135.09162 (calcd 135.09167 for C8H11N2, [M+1]+). 
 
4.5.2. 2-Ethynyl-1,4-dimethyl-5-phenyl-1H-imidazole (6b). Yield: 0.094 g (48%). 
Pale yellow oil (Al2O3, AcOEt/hexane 3:7). IR (ﬁlm): ν 3230br, 2918m, 2109m, 
1566m, 1487m, 1449m, 1390m, 1018m, 762m, 707m, 655m, 635m. 1H NMR (CDCl3): 
δ 7.48–7.44 (m, 2H, HC(arom.)); 7.41–7.37 (m, 1H, HC(arom.)); 7.31–7.27 (m, 2H, 
HC(arom.)); 3.58 (s, 3H, Me); 3.36 (s, 1H, HC); 2.20 (s, 3H, Me). 13C NMR (CDCl3): δ 
136.2, 130.2, 130.0, 129.8 (C(arom.), 3 C(imid.)); 129.8, 128.7, 128.2 (5 CH(arom.)); 
81.3, 73.8 (C≡C); 32.3 (Me); 13.4 (Me). HR-ESI-MS (MeOH): 197.10756 (calcd 
197.10732 for C13H13N2, [M+1]+). 
 
4.5.3. 2-Ethynyl-1-methyl-4,5-diphenyl-1H-imidazole (6c). Yield: 0.126 g (49%). 
Pale yellow oil (Al2O3, AcOEt/hexane 3:7). IR (KBr): ν 3299br, 2924m, 2853m, 
2118m, 1599m, 1504m, 1478m, 1461m, 1447m, 1387m, 1073m, 964m, 778m, 756m, 
697m. 1H NMR (CDCl3): δ 7.53–7.47 (m, 5H, HC(arom.)); 7.38–7.34 (m, 2H, 
HC(arom.)); 7.24–7.16 (m, 3H, HC(arom.)); 3.57 (s, 3H, Me); 3.44 (s, 1H, HC). 13C 
NMR (CDCl3): δ 138.6, 133.9, 130.8, 130.3, 130.2 (2 C(arom.), 3 C(imid.)); 130.6, 
129.1, 128.9, 128.1, 126.9, 126.7 (10 CH(arom.)); 81.8, 73.6 (C≡C); 32.1 (Me). HR-
ESI-MS (MeOH): 259.12283 (calcd 259.12298 for C18H15N2, [M+1]+). 
 
4.5.4. 1-Butyl-2-ethynyl-4,5-dimethyl-1H-imidazole (6d). Yield: 0.089 g (51%). Pale 
yellow oil (Al2O3, AcOEt/hexane 3:7). IR (film): ν 3428br, 2958m, 2872m, 2112m, 
1735m, 1578m, 1467m, 1410m, 1369m, 1214m, 1007m, 830m, 704m. 1H NMR 
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(CDCl3): δ 3.94–3.89 (m, 2H, H2C); 3.28 (s, H, HC); 2.14 (s, 3H, Me); 2.13 (s, 3H, 
Me); 1.70–1.64 (m, 2H, H2C); 1.39–1.32 (m, 2H, H2C); 0.94 (t = 7.2 Hz, 3H, Me). 13C 
NMR (CDCl3): δ 134.7, 128.4, 123.9 (3 C(imid.)); 80.3, 74.2 (C≡C); 44.6 (CH2); 32.6 
(CH2); 19.8 (CH2); 13.6 (Me); 12.8 (Me); 8.9 (Me). HR-ESI-MS (MeOH): 177.13848 
(calcd 177.13863 for C11H17N2, [M+1]+). 
 
4.5.5. 1-Butyl-2-ethynyl-4-methyl-5-phenyl-1H-imidazole (6e). Yield: 0.099 g 
(42%). Pale yellow oil (Al2O3, AcOEt/hexane 3:7). IR (film): ν 3336br, 2959m, 2123m, 
1489m, 1460m, 1405m, 1377m, 1315m, 761m, 702m, 610m, 596m, 508m, 454m. 1H 
NMR (CDCl3): δ 7.47–7.43 (m, 2H, HC(arom.)); 7.41–7.38 (m, 1H, HC(arom.)); 7.29–
7.26 (m, 2H, HC(arom.)); 3.98–3.94 (m, 2H, H2C); 3.34 (s, 1H, HC); 2.16 (s, 3H, Me); 
1.55–1.49 (m, 2H, H2C); 1.19–1.12 (m, 2H, H2C); 0.77 (t = 7.2 Hz, 3H, Me). 13C NMR 
(CDCl3): δ 136.3, 130.1, 129.7, 129.5 (C(arom.), 3 C(imid.)); 129.9, 128.7, 128.2 (5 
HC(arom.)); 80.9, 74.0 (C≡C); 44.9 (CH2); 32.5 (CH2); 19.5 (CH2); 13.4 (Me); 13.2 
(Me). HR-ESI-MS (MeOH): 239.15403 (calcd 239.15428 for C16H19N2, [M+1]+). 
 
4.6. General procedure for the synthesis of compounds 8 
 
To a solution of the corresponding acetylene derivative 6 (1 mmol) and CuI (0.2 
mmol) in acetonitrile (3 mL) under argon atmosphere, Et3N (3 mL) was added. After 15 
min, to the yellow reaction mixture was added azide 718 (1 mmol) in acetonitrile (2 mL) 
dropwise and heated at 40 °C for 2 h. Next, H2O was added and the mixture was 
extracted with CH2Cl2 (3×15 mL). The organic layers were combined and dry with 
Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The 
residue was diluted in CH2Cl2 (3 mL) and trifluoroacetic acid (1.5 equiv.) in CH2Cl2 (2 
mL) was added. After all of the intermediate was consumed (monitored by TLC), the 
solvent was evaporated and the residue was dissolved in CH2Cl2 (4 mL). Then, 
NaHCO3 was added and the mixture was magnetically stirred for 5 h. Next, the solid 
was filtered and the filtrate was concentrated by evaporation in a rotary evaporator. The 
crude product 8 was purified by column chromatography. 
 
4.6.1. 4-(1,4,5-Trimethyl-1H-imidazol-2-yl)-1-[((S)-pyrrolidin-2-yl)methyl]-1,2,3-
triazole (8a). Yield: 0.119 g (46%). Pale yellow oil (SiO2, CHCl3/MeOH 9:1). IR 
(film): ν 3399br, 2903m, 2824m, 1646m, 1582m, 1459m, 1289m, 1213m, 1013m, 
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856m, 748m, 618m. 1H NMR (CDCl3): δ 8.22 (s, 1H, HC(triaz.)); 4.46–4.40 (m, 1H, 
HC); 4.34–4.28 (m, 1H, H2C); 3.95 (s, 3H, Me); 3.69–3.63 (m, 1H, H2C); 3.04–2.94 (m, 
2H, H2C); 2.21 (s, 3H, Me); 2.21 (s, 3H, Me); 2.01–1.94 (m, 1H, H2C); 1.85–1.72 (m, 
2H, H2C); 1.57–1.49 (m, 1H, H2C). 13C NMR (CDCl3): δ 141.2, 136.9, 133.2, 124.5 (3 
C(imid.), C(triaz.)); 123.1 (CH(triaz.)); 57.9 (CH); 55.3 (CH2); 46.4 (CH2); 32.1 (Me); 
29.1 (CH2); 25.3 (CH2); 12.6 (Me); 8.8 (Me). HR-ESI-MS (MeOH): 261.18240 (calcd 
261.18222 for C13H21N6, [M+1]+). [α]D25 = –26 (c 0.5, CH2Cl2). 
 
4.6.2. 4-(1,4-Dimethyl-5-phenyl-1H-imidazol-2-yl)-1-[((S)-pyrrolidin-2-yl)methyl]-
1,2,3-triazole (8b). Yield: 0.197 g (61%). Pale yellow oil (SiO2, CHCl3/MeOH 9:1). IR 
(ﬁlm): ν 3420br, 2925m, 2854m, 2468m, 1683m, 1635m, 1480m, 1312m, 1203m, 
1177m, 1131m, 1048m, 1017m, 833m, 801m, 721m, 703m. 1H NMR (CDCl3): δ 8.53 
(s, 1H, HC(triaz.)); 7.37–7.30 (m, 3H, HC(arom.)); 7.16–7.13 (m, 2H, HC(arom.)); 
4.71–4.58 (m, 2H, H2C); 4.01–3.94 (m, 1H, HC); 3.52 (s, 3H, Me); 3.32–3.25 (m, 1H, 
H2C); 3.16–3.09 (m, 1H, H2C); 2.16 (s, 3H, Me); 2.16–2.08 (m, 1H, H2C); 2.06–1.97 
(m, 1H, H2C); 1.94–1.85 (m, 1H, H2C); 1.79–1.69 (m, 1H, H2C). 13C NMR (CDCl3): δ 
139.8, 138.9, 134.9, 130.6, 130.1, 129.5, 128.8, 128.1 (C(arom.), 3 C(imid.), C(triaz.), 5 
CH(arom.)); 123.2 (CH(triaz.)); 59.9 (CH); 52.9 (CH2); 45.6 (CH2); 32.9 (Me); 28.7 
(CH2); 24.1 (CH2); 12.8 (Me). HR-ESI-MS (MeOH): 323.19803 (calcd 323.19787 for 
C18H23N6, [M+1]+). [α]D25 = –19 (c 0.625, CH2Cl2). 
 
4.6.3. 4-(1-Methyl-4,5-diphenyl-1H-imidazol-2-yl)-1-[((S)-pyrrolidin-2-yl)methyl]-
1,2,3-triazole (8c). Yield: 0.276 g (65%). Pale yellow crystals. Mp. 52–54 °C 
(MeOH/hexane). IR (film): ν 3424br, 2954m, 2854m, 2202m, 2173m, 1683m, 1602m, 
1503m, 1443m, 1400m, 1202m, 1133m, 1055m, 722m, 696m, 640m. 1H NMR (CDCl3): 
δ 8.45 (s, 1H, HC(triaz.)); 7.44–7.39 (m, 5H, HC(arom.)); 7.34–7.30 (m, 2H, 
HC(arom.)); 7.20–7.16 (m, 2H, HC(arom.)); 7.15–7.11 (m, 1H, HC(arom.)); 4.60–4.54 
(m, 2H, H2C); 3.83–3.77 (m, 1H, HC); 3.77 (s, 3H, Me); 3.14–3.08 (m, 1H, H2C); 3.05–
2.99 (m, 1H, H2C); 2.04–1.96 (m, 1H, H2C); 1.91–1.84 (m, 1H, H2C); 1.80–1.71 (m, 
1H, H2C); 1.68–1.60 (m, 1H, H2C). 13C NMR (CDCl3): δ 140.2, 138.9, 137.9 (3 
C(imid.)); 134.4, 130.9, 130.8, 130.3, 129.0, 128.7, 128.2, 127.2, 126.7 (2 C(arom.), 
C(triaz.), 10 CH(arom.)); 124.3 (CH(triaz.)); 58.7 (CH); 53.5 (CH2); 46.1 (CH2); 33.1 
(Me); 28.9 (CH2); 24.7 (CH2). HR-ESI-MS (MeOH): 385.21378 (calcd 385.21352 for 
C23H25N6, [M+1]+). [α]D25 = –29 (c 0.5, CH2Cl2). 
 13 
 
4.6.4. 4-(1-Butyl-4,5-dimethyl-1H-imidazol-2-yl)-1-[((S)-pyrrolidin-2-yl)methyl]-
1,2,3-triazole (8d). Yield: 0.117 g (39%). Pale yellow oil (SiO2, CHCl3/MeOH 9:1). IR 
(film): ν 3400br, 2968m, 2854m, 1625m, 1562m, 1477m, 1399m, 1286m, 1050m, 
812m, 733m, 599m. 1H NMR (CDCl3): δ 8.32 (s, 1H, HC(triaz.)); 4.66–4.57 (m, 1H, 
H2C); 4.54–4.46 (m, 1H, H2C); 4.11–3.99 (m, 2H, H2C); 3.91–3.82 (m, 1H, HC); 3.45–
3.36 (m, 1H, H2C); 3.23–3.12 (m, 1H, H2C); 3.19–3.00 (m, 1H, H2C); 2.12 (s, 3H, Me); 
2.09 (s, 3H, Me); 2.06–1.98 (m, 1H, H2C); 1.96–1.88 (m, 1H, H2C); 1.85–1.77 (m, 1H, 
H2C); 1.69–1.60 (m, 1H, H2C); 1.57–1.37 (m, 3H, H2C); 0.85 (t = 7.2 Hz, 3H, Me). 13C 
NMR (CDCl3): δ 139.7, 136.4, 132.9, 124.0 (3 C(imid.), C(triaz.)); 122.9 (CH(triaz.)); 
59.1 (CH); 54.4 (CH2); 53.3 (CH2); 45.7 (CH2); 44.6 (CH2); 32.6 (CH2); 28.9 (CH2); 
24.4 (CH2); 13.6 (Me); 12.2 (Me); 8.7 (Me). HR-ESI-MS (MeOH): 303.22922 (calcd 
303.22917 for C16H27N6, [M+1]+). [α]D25 = –32 (c 0.5, CH2Cl2). 
 
4.6.5. 4-(1-Butyl-4-methyl-5-phenyl-1H-imidazol-2-yl)-1-[((S)-pyrrolidin-2-
yl)methyl]-1,2,3-triazole (8e). Yield: 0.174 g (48%). Pale yellow oil (SiO2, 
CHCl3/MeOH 9:1). IR (film): ν 3398br, 2953m, 2862m, 1614m, 1538m, 1443m, 
1402m, 1279m, 1039m, 829m, 730m, 608m. 1H NMR (CDCl3): δ 8.21 (s, 1H, 
HC(triaz.)); 7.42–7.37 (m, 2H, HC(arom.)); 7.35–7.31 (m, 1H, HC(arom.)); 7.28–7.25 
(m, 2H, HC(arom.)); 4.40–4.22 (m, 4H, H2C); 3.67–3.56 (m, 1H, HC); 2.96–2.84 (m, 
2H, H2C); 2.12 (s, 3H, Me); 1.93–1.86 (m, 1H, H2C); 1.77–1.66 (m, 2H, H2C); 1.48–
1.40 (m, 3H, H2C); 1.09–1.01 (m, 2H, H2C); 0.63 (t = 7.2 Hz, 3H, Me). 13C NMR 
(CDCl3): δ 140.9, 135.3, 130.7, 130.1, 125.9 (3 C(imid.), C(arom.), C(triaz.)); 130.4 (2 
HC(arom.)); 128.6, 127.9 (3 HC(arom.)); 123.6 (CH(triaz.)); 61.8 (CH); 55.3 (CH2); 
46.5 (CH2); 44.9 (CH2); 32.9 (CH2); 29.2 (CH2); 25.4 (CH2); 19.3 (CH2); 13.4 (Me); 
13.1 (Me). HR-ESI-MS (MeOH): 365.24494 (calcd 365.24482 for C21H29N6, [M+1]+). 
[α]D25 = –16 (c 0.625, CH2Cl2). 
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